Trial Profile
Olmesartan medoxomil/amlodipine versus olmesartan medoxomil/hydrochlorothiazide in hypertensive patients with metabolic syndrom: the OLAS study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 May 2012
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/amlodipine (Primary) ; Olmesartan medoxomil/hydrochlorothiazide (Primary) ; Olmesartan medoxomil
- Indications Hypertension; Metabolic syndrome
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms OLAS
- 13 May 2012 Status changed from not stated to completed.
- 29 Apr 2012 Results presented at the 22nd European Meeting on Hypertension.
- 05 Nov 2010 New trial record.